racemetirosine has been researched along with Atherosclerotic Parkinsonism in 5 studies
alpha-Methyltyrosine: An inhibitor of the enzyme TYROSINE 3-MONOOXYGENASE, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with PHEOCHROMOCYTOMA. (Martindale, The Extra Pharmacopoeia, 30th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the present study was to assess the efficacy of pramipexole (2-amino-4,5,6, 7-tetrahydro-6-propyl-amino-benzthiazole-dihydrochloride), a new dopamine D(2)/D(3) receptor agonist, to attenuate parkinsonian-like muscle rigidity in rats." | 7.70 | Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats. ( Lorenc-Koci, E; Wolfarth, S, 1999) |
| "The aim of the present study was to assess the efficacy of pramipexole (2-amino-4,5,6, 7-tetrahydro-6-propyl-amino-benzthiazole-dihydrochloride), a new dopamine D(2)/D(3) receptor agonist, to attenuate parkinsonian-like muscle rigidity in rats." | 3.70 | Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats. ( Lorenc-Koci, E; Wolfarth, S, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sotnikova, TD | 1 |
| Beaulieu, JM | 1 |
| Barak, LS | 1 |
| Wetsel, WC | 1 |
| Caron, MG | 1 |
| Gainetdinov, RR | 1 |
| Fahn, S | 1 |
| Laruelle, M | 1 |
| D'Souza, CD | 1 |
| Baldwin, RM | 1 |
| Abi-Dargham, A | 1 |
| Kanes, SJ | 1 |
| Fingado, CL | 1 |
| Seibyl, JP | 1 |
| Zoghbi, SS | 1 |
| Bowers, MB | 1 |
| Jatlow, P | 1 |
| Charney, DS | 1 |
| Innis, RB | 1 |
| Hughes, NR | 1 |
| McKnight, AT | 1 |
| Woodruff, GN | 1 |
| Hill, MP | 1 |
| Crossman, AR | 1 |
| Brotchie, JM | 1 |
| Lorenc-Koci, E | 1 |
| Wolfarth, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of Carbidopa/l-Dopa and Carbidopa/l Dopa/Entacapone on Synaptic Dopamine in Parkinson's Patients: An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)[NCT00200447] | Phase 2 | 3 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics[NCT03430596] | Early Phase 1 | 50 participants (Actual) | Interventional | 2018-05-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 other studies available for racemetirosine and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease.
Topics: alpha-Methyltyrosine; Amphetamines; Animals; Antiparkinson Agents; Basal Ganglia; Blepharoptosis; Di | 2005 |
Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents.
Topics: Adult; Aged; alpha-Methyltyrosine; Carbidopa; Dopamine; Dopamine Antagonists; Drug Therapy, Combinat | 1983 |
Imaging D2 receptor occupancy by endogenous dopamine in humans.
Topics: Adult; Affect; alpha-Methyltyrosine; Animals; Benzamides; Brain; Dopamine; Enzyme Inhibitors; Homova | 1997 |
Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism.
Topics: alpha-Methyltyrosine; Animals; Antiparkinson Agents; Benzeneacetamides; Benzofurans; Dose-Response R | 1998 |
Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats.
Topics: alpha-Methyltyrosine; Animals; Benzothiazoles; Dopamine Agonists; Dose-Response Relationship, Drug; | 1999 |